Mersana Therapeutics (MRSN) Announces Positive Interim Data from Expansion Portion of the XMT-1536 Phase 1 Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SKA-B
3. PBA
4. ALAR
5. CCH:LN
6. META
7. CCHGY
8. PRY:IM
9. PRYMY
10. SPY

Go back to Mersana Therapeutics (MRSN) Announces Positive Interim Data from Expansion Portion of the XMT-1536 Phase 1 Study

Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study

May 27, 2020 6:00 AM EDT

- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer

- Data continue to support a NaPi2b biomarker-based patient selection strategy

- Generally well-tolerated with no new safety signals

- Data to be presented on a conference call today at 8 a.m. ET and at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020

CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:... More